Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).
Navani V, Ernst M, Wells C, Yuasa T, Takemura K, Donskov F, Basappa N, Schmidt A, Pal S, Meza L, Wood L, Ernst D, Szabados B, McKay R, Weickhardt A, Suárez C, Kapoor A, Lee J, Choueiri T, Heng D. Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 310-310. DOI: 10.1200/jco.2022.40.6_suppl.310.Peer-Reviewed Original ResearchAssociated with responseCytoreductive nephrectomyIpi-nivoLung metastasesMetastatic renal cell carcinomaPresence of lung metastasesResponse to first-lineImmunotherapy combination regimensMedian overall survivalRenal cell carcinomaPredictors of responseEndothelial growth factorIpilimumab-nivolumabSarcomatoid histologyRECIST v1.1Combination regimensOverall survivalCombination therapyCell carcinomaFirst-lineResponse of CRNon-respondersPrognostic riskClinical variablesPatient counselingFirst-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Roussel E, Kinget L, Beuselinck B, Albersen M, Wells C, Ernst M, Donskov F, Schmidt A, Szabados B, Pal S, Meza L, Agarwal N, Weickhardt A, Davis I, Alva A, Wood L, Porta C, Choueiri T, Heng D, Navani V. First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 317-317. DOI: 10.1200/jco.2022.40.6_suppl.317.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumMetastatic renal cell carcinomaPancreatic metastasisOverall survivalVascular endothelial growth factorRenal cell carcinomaMedian OSCell carcinomaInternational Metastatic Renal Cell Carcinoma Database Consortium risk groupMetastatic renal cell carcinoma patientsMedian OS of patientsRetrospective analysis of patientsEfficacy of first-lineKaplan Meier survival curvesOS of patientsSite of metastasisFirst-line therapyAssociated with improved outcomesIndolent biological behaviorAnalysis of patientsAnti-angiogenic therapyVEGF monotherapyEndothelial growth factorLow event ratesImproved OSCABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Navani V, Wells C, Boyne D, Cheung W, Brenner D, McGregor B, Labaki C, Schmidt A, McKay R, Pal S, Meza L, Donskov F, Beuselinck B, Ernst M, Otiato M, Ludwig L, Powles T, Szabados B, Choueiri T, Heng D. CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 318-318. DOI: 10.1200/jco.2022.40.6_suppl.318.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumIpilimumab-nivolumabTreatment failureOverall survivalInternational Metastatic Renal Cell Carcinoma Database Consortium criteriaInternational Metastatic Renal Cell Carcinoma Database Consortium risk groupAdvanced renal cell carcinomaResponse rateActivity of cabozantinibClinically meaningful activityRenal cell carcinomaEndothelial growth factorCell histologySarcomatoid componentBone metastasesVEGF inhibitorsPoor riskCell carcinomaCabozantinibHazard ratioRisk groupsPatientsGrowth factorTherapyEarly lines